Recommendation of the President – Phesgo (pertuzumab/trastuzumab)

On 7 August 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 113/2025 on the appraisal of the medicinal product Phesgo (pertuzumab/trastuzumab) under the B.9.FM drug program. “Treatment of patients with breast cancer (ICD-10: C50)”

Publication in Public Information Bulletin (BIP) >>